|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Dicerna Pharmaceuticals Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator
3/19/2013 10:09:55 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-stranded RNAs directed against the important oncology gene target KRAS. U.S. patent 8,372,816, titled “Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA” was recently issued to Dicerna. This issuance continues the expansion of Dicerna’s patent portfolio around RNAi-related technology, including the DsiRNA class defining claims of U.S. patent 8,084,599, titled “Methods and compositions for the specific inhibition of gene expression by double-stranded RNA.”
|
|
|
|
|
|
|
|
|
|
|